You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Mallinckrodt
Medtronic
Moodys
Harvard Business School

Last Updated: June 2, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for CHS-828


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the drug development status for CHS-828?

CHS-828 is an investigational drug.

There have been 15 clinical trials for CHS-828. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2020.

The most common disease conditions in clinical trials are Psoriasis, Arthritis, Rheumatoid, and Hyperemesis Gravidarum. The leading clinical trial sponsors are Coherus Biosciences, Inc., Baxalta US Inc., and Daiichi Sankyo Co., Ltd.

There are eighteen US patents protecting this investigational drug and two hundred and sixty-three international patents.

Recent Clinical Trials for CHS-828
TitleSponsorPhase
Treatment Strategies in CHSCanadian Institutes of Health Research (CIHR)Phase 4
Treatment Strategies in CHSUniversity of CalgaryPhase 4
Improving Pain Control in Paraesophageal Hernia Repair: Intravenous Lidocaine Versus PlaceboAtrium HealthPhase 4

See all CHS-828 clinical trials

Clinical Trial Summary for CHS-828

Top disease conditions for CHS-828
Top clinical trial sponsors for CHS-828

See all CHS-828 clinical trials

US Patents for CHS-828

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
CHS-828   Start Trial Compounds and compositions for the inhibition of NAMPT Forma TM, LLC (Watertown, MA) Genentech, Inc. (South San Francisco, CA)   Start Trial
CHS-828   Start Trial Compounds and compositions for the inhibition of NAMPT FORMA TM, LLC (Watertown, MA) Genentech, Inc. (South San Francisco, CA)   Start Trial
CHS-828   Start Trial Methods and compositions for treatment of demyelinating diseases Pathologica LLC (San Francisco, CA)   Start Trial
CHS-828   Start Trial N-cyano-N'-pyridylguanidines as serotonin antagonists Leo Pharmaceutical Products Ltd. (Ballerup, DK)   Start Trial
CHS-828   Start Trial Cyanoguanidine prodrugs Leo Pharmaceutical Products Ltd. A/S (Ballerup, DK)   Start Trial
CHS-828   Start Trial Cyanoguanidine prodrugs LEO Pharma A/S (Ballerup, DK)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for CHS-828

Drugname Country Document Number Estimated Expiration Related US Patent
CHS-828 Argentina 082885 2030-09-03   Start Trial
CHS-828 Australia 2011295725 2030-09-03   Start Trial
CHS-828 Brazil 112013004773 2030-09-03   Start Trial
CHS-828 Canada 2810038 2030-09-03   Start Trial
CHS-828 Chile 2013000588 2030-09-03   Start Trial
CHS-828 China 103384668 2030-09-03   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Boehringer Ingelheim
Express Scripts
McKesson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.